Clinical Trials Logo

Renal Transplant Rejection clinical trials

View clinical trials related to Renal Transplant Rejection.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03780101 Terminated - Clinical trials for Chronic Kidney Diseases

Pathology and Imaging in Kidney Allografts

PIKA
Start date: February 15, 2019
Phase:
Study type: Observational

This study will perform multi-parametric renal MRI in 70 patients with a renal transplant who are undergoing a clinically indicated biopsy of their transplant. The aim of this study is to compare findings on renal MRI with those seen on histology.

NCT ID: NCT03646344 Terminated - Clinical trials for Renal Transplant Rejection

Heme Arginate in Transplantation Study

HOT2
Start date: March 12, 2019
Phase: Phase 3
Study type: Interventional

Organ shortage for transplant has necessitated use of kidneys from older donors, increasing the chance that the kidney will not work immediately or for as long as expected. The investigators gave the drug heme arginate (HA) to 20 kidney transplant patients in the first 24 hours after transplant, and showed that it may reduce kidney injury and is safe. The investigators plan to conduct a large study recruiting 600 patients to determine whether HA treatment increases the number of kidney transplants that work immediately. If successful, HA may be introduced into clinical practice at the end of this study. Patients will be invited to take part in the study once listed for a kidney transplant. Further discussions will be had with them when admitted for transplant, and they will be offered the opportunity to participate. Consent will not be taken until the patient is admitted for transplantation. Following consent, participants will be randomised to receive either 2 doses of the study drug, HA, or a salt water solution, one at the time of transplant, and one approximately 24 hours later. Otherwise, treatment will be the same as any other patient undergoing a kidney transplant. Information about recovery from surgery, and specifically about kidney function, will be collected, but will not require additional blood tests. The study period ends after the first 7 days post-transplant, although longer term data will be collected from routine follow up appointments. Participants will be asked to complete a simple quality of life questionnaire 3 times: just before transplant, at approximately one week and three months after transplant.

NCT ID: NCT01413685 Terminated - Clinical trials for Renal Transplant Rejection

Calcineurin Activity in Renal Recipients

Start date: January 2009
Phase: Phase 4
Study type: Interventional

The purpose is to define if calcineurin activity is a better biological parameter than blood concentration for the therapeutic tacrolimus monitoring.

NCT ID: NCT01324934 Terminated - Clinical trials for Renal Transplant Rejection

Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

IBERICA
Start date: October 2006
Phase: Phase 3
Study type: Interventional

The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year after renal transplantation.

NCT ID: NCT00983645 Terminated - Clinical trials for Renal Transplant Rejection

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

Start date: October 2004
Phase: Phase 4
Study type: Interventional

This study aims to compare outcomes in renal transplant recipients in the hispanic population based on their immunosuppressant regimens.